The growth hormone response to pyridostigmine plus growth hormone releasing hormone is not influenced by pubertal maturation

What Was Tested

This controlled clinical trial paper looks at GHRH (Growth Hormone-Releasing Hormone).

The researchers have evaluated the effect of pubertal maturation on the GH response to growth hormone releasing hormone (GHRH), pyridostigmine (PD) and the combined administration of PD + GHRH in a group of short normal children.

Fifteen were prepubertal (13 boys and 2 girls, age 5.0 - 12.5 yr), 10 were early pubertal (8 boys and 2 girls, age 11.5 - 16.9 yr in Tanner stage 2-3 of pubertal maturation), and 6 were late pubertal (6 boys and 2 girls, age 13.6 - 17.1 yr in Tanner stage 4-5 of pubertal maturation).

Who Took Part

The study group was 13 boys.

The age groups tagged for this paper are young children, children and teenagers, both men and women.

What Was Measured

The researchers have evaluated the effect of pubertal maturation on the GH response to growth hormone releasing hormone (GHRH), pyridostigmine (PD) and the combined administration of PD + GHRH in a group of short normal children.

The subject headings attached to it are Drug Synergism, Growth Disorders, Growth Hormone, Growth Hormone-Releasing Hormone, Puberty and Pyridostigmine Bromide.

What This Means in Plain Language

This is a controlled clinical trial of GHRH (Growth Hormone-Releasing Hormone) in 13 boys.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1991 (Journal of endocrinological investigation), a journal based in Italy.

More context: the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.